HK inno.N Corporation (KOSDAQ:195940)

Market Cap	1.36T +32.0%
Revenue (ttm)	839.63B +12.9%
Net Income	41.49B +58.1%
EPS	1,451.65 +96.5%
Shares Out	28.33M
PE Ratio	33.10
Forward PE	14.76
Dividend	350.00 (0.72%)
Ex-Dividend Date	Mar 30, 2026

Volume	117,338
Average Volume	129,210
Open	49,000
Previous Close	48,050
Day's Range	48,050 - 49,100
52-Week Range	31,650 - 58,600
Beta	0.65
RSI	44.51
Earnings Date	Apr 29, 2026

About HK inno.N

HK inno.N Corporation engages in the pharmaceutical business in South Korea. The company offers prescription drugs for the treatment of gram-positive and gram-negative organisms, enterococcus faecium infections, vancomycin-resistant, acute bacterial sinusitis, bronchitis, neumonia, antibiotics, and infections caused by microorganism; anemia and hemodialysis; diabetes; hypertension, primary hypercholesterinemia, homozygous familial hypercholesterolemia, and hypertension with dyslipidemia; GERD, EE, NERD, GU and H.Pylori; pleural mesothelioma, no...

• Industry: Medical Care Facilities
• Sector: Healthcare
• Founded: 1984
• Employees: 1,695
• Stock Exchange: KOSDAQ
• Ticker Symbol: 195940

Financial Performance

In 2021, HK inno.N's revenue was 769.79 billion, an increase of 28.63% compared to the previous year's 598.45 billion. Earnings were 21.35 billion, a decrease of -23.49%.